Liver disease in cystic fibrosis: An update

Hepatitis Monthly

Volumn 13, Issue 8, 2013, Pages 8-

  Parisi, Giuseppe Fabio ^a   Di Dio, Giovanna ^a   Franzonello, Chiara ^a   Gennaro, Alessia ^a   Rotolo, Novella ^a   Lionetti, Elena ^a   Leonardi, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cystic fibrosis; Liver disease; Mutation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOGLIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTERSTITIAL COLLAGENASE; MANNOSE BINDING LECTIN 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

ALLELE; BILIARY CIRRHOSIS; CHROMOSOME 7; CYSTIC FIBROSIS; ECHOGRAPHY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEPATOBILIARY DISEASE; HUMAN; JAUNDICE; LIVER DISEASE; LIVER INJURY; LIVER TRANSPLANTATION; LUNG FUNCTION; PORTAL HYPERTENSION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SCLEROSIS;

EID: 84883169323     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.11215     Document Type: Review

References (74)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.
2. Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol. 2004;41(6):1041-4.
3. Kreindler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther. 2010;125(2):219-29.
4. Gregory RJ, Cheng SH, Rich DP, Marshall J, Paul S, Hehir K, et al. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature. 1990;347(6291):382-6.
5. Castellani C, Cuppens H, Macek M, Jr, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179-96.
6. Tsui LC. The spectrum of cystic fibrosis mutations. Trends in Genetics. 1992;8(11):392-8.
7. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995;29:777-807.
8. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem. 1999;274(31):21873-7.
9. Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2009;25(3):272-8.
10. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41(6):920-5.
11. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):1374-82.
12. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30(5):1151-8.
13. Debray D, Lykavieris P, Gauthier F, Dousset B, Sardet A, Munck A, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999;31(1):77-83.
14. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. The Journal of pediatrics. 1994;124(3):393-9.
15. Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr. 2004;145(3):327-32.
16. Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 1999;103(1):52-7.
17. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):1857-64.
18. Kinnman N, Lindblad A, Housset C, Buentke E, Scheynius A, Strandvik B, et al. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology. 2000;32(2):334-40.
19. Flass T, Narkewicz M. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12(2):116-24.
20. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic fibrosis. Paediatr Respir Rev. 2001;2(4):340-9.
21. Lewindon PJ, Pereira TN, Hoskins AC, Bridle KR, Williamson RM, Shepherd RW, et al. The Role of Hepatic Stellate Cells and Transforming Growth Factor-β1 in Cystic Fibrosis Liver Disease. The American journal of pathology. 2002;160(5):1705-15.
22. Pereira TN, Lewindon PJ, Smith JL, Murphy TL, Lincoln DJ, Shepherd RW, et al. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol. 2004;41(4):576-83.
23. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28 Suppl 1:S1-13.
24. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol res pract. 2010;2010.
25. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22 Suppl 1:S73-8.
26. Norman K, Pirlich M. Gastrointestinal tract in liver disease: which organ is sick? Curr Opin Clin Nutr Metab Care. 2008;11(5):613-9.
27. Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF. Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis. 2010;30(3):232-44.
28. Zeuzem S. Gut-liver axis. Int J Colorectal Dis. 2000;15(2):59-82.
29. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. The Lancet. 2003;361(9370):1671-6.
30. Castaldo G, Fuccio A, Salvatore D, Raia V, Santostasi T, Leonardi S, et al. Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. American Journal of Medical Genetics. 2001;98(4):294-7.
31. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302(10):1076-83.
32. Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, et al. Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr. 2012;54(3):328-35.
33. Colombo C, Crosignani A, Battezzati P M. Liver involvement in cystic fibrosis. J Hepatol. 1999;31(5):946-54.
34. Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24(5):585-92.
35. Lewindon PJ, Shepherd RW, Walsh MJ, Greer RM, Williamson R, Pereira TN, et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology. 2011;53(1):193-201.
36. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006;44(1):197-208.
37. Haber HP. Cystic fibrosis in children and young adults: findings on routine abdominal sonography. AJR Am J Roentgenol. 2007;189(1):89-99.
38. Akata D, Akhan O, Özcelik U, Özmen M N, Oguzkurt L, Haliloglu M, et al. Hepatobiliary manifestations of cystic fibrosis in children: correlation of CT and US findings. Eur j radiol 2002;41(1):26-33.
39. Men S, Yuce A, Ozmen M, Akhan O, Kale G. Unusual appearance of the liver on ultrasonography and computed tomography in a patient with cystic fibrosis. Turk J Pediatr. 1993;35(2):135-40.
40. Angelico M, Gandin C, Canuzzi P, Bertasi S, Cantafora A, De Santis A, et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology. 1991;14(5):768-75.
41. O'Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG. Hepatocellular carcinoma complicating cystic fibrosis related liver disease. J Cyst Fibros. 2009;8(4):288-90.
42. McKeon D, Day A, Parmar J, Alexander G, Bilton D. Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis. J Cyst Fibros. 2004;3(3):193-5.
43. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch Dis Child. 1993;68(5):653-7.
44. Rowland M, Gallagher CG, O'Laoide R, Canny G, Broderick A, Hayes R, et al. Outcome in cystic fibrosis liver disease. Am J Gastroenterol. 2011;106(1):104-9.
45. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10:S29-S36.
46. Colombo C, Russo MC, Zazzeron L, Romano G. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2006;43 Suppl 1:S49-55.
47. Woodruff SA, Sontag MK, Accurso F, Sokol RJ, Narkewicz MR. Prevalence of elevated liver function tests in children with cystic fibrosis diagnosed by newborn screen. J Pediatr Gastroenterol Nutr. 2007;45.
48. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr. 1997;25(1):32-6.
49. Shapira R, Hadzic N, Francavilla R, Koukulis G, Price JF, Mieli-Vergani G. Retrospective review of cystic fibrosis presenting as infantile liver disease. Arch Dis Child. 1999;81(2):125-8.
50. Lenaerts C, Lapierre C, Patriquin H, Bureau N, Lepage G, Harel F, et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. The Journal of pediatrics. 2003;143(3):343-50.
51. Patriquin H, Lenaerts C, Smith L, Perreault G, Grignon A, Filiatrault D, et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology. 1999;211(1):229-32.
52. Stewart L. The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease. J R Soc Med. 2005;98 Suppl 45:17-27.
53. Williams SGJ, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol. 1995;22(5):513-21.
54. Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J Cyst Fibros. 2008;7(3):215-21.
55. Witters P, De Boeck K, Dupont L, Proesmans M, Vermeulen F, Servaes R, et al. Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros. 2009;8(6):392-9.
56. Vergesslich KA, Gotz M, Mostbeck G, Sommer G, Ponhold W. Portal venous blood flow in cystic fibrosis: assessment by Duplex Doppler sonography. Pediatr Radiol. 1989;19(6-7):371-4.
57. King LJ, Scurr ED, Murugan N, Williams SG, Westaby D, Healy JC. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics. 2000;20(3):767-77.
58. Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. Radiographics. 1996;16(4):871-93.
59. Fields TM, Michel SJ, Butler CL, Kriss VM, Albers SL. Abdominal manifestations of cystic fibrosis in older children and adults. AJR Am J Roentgenol. 2006;187(5):1199-203.
60. Soyer P, Spelle L, Pelage JP, Dufresne AC, Rondeau Y, Gouhiri M, et al. Cystic fibrosis in adolescents and adults: fatty replacement of the pancreas--CT evaluation and functional correlation. Radiology. 1999;210(3):611-5.
61. Leonardi S, Giambusso F, Sciuto C, Castiglione S, Castiglione N, La Rosa M. Are Serum Type III Procollagen and Prolyl Hydroxylase Useful as Noninvasive Markers of Liver Disease in Patients with Cystic Fibrosis? J Pediatr Gastroenterol Nutr. 1998;27(5):603-5.
62. Wyatt HA, Dhawan A, Cheeseman P, Mieli-Vergani G, Price JF. Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child. 2002;86(3):190-3.
63. Rath T, Hage L, Kugler M, Menendez Menendez K, Zachoval R, Naehrlich L, et al. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8(3).
64. Smith JL, Lewindon PJ, Hoskins AC, Pereira TN, Setchell KD, O'Connell NC, et al. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology. 2004;39(6):1673-82.
65. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology. 1996;23(6):1484-90.
66. Siano M, De Gregorio F, Boggia B, Sepe A, Ferri P, Buonpensiero P, et al. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis. 2010;42(6):428-31.
67. Fridell JA, Bond GJ, Mazariegos GV, Orenstein DM, Jain A, Sindhi R, et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. Journal of pediatric surgery. 2003;38(8):1152-6.
68. Ikegami T, Sanchez EQ, Uemura T, Narasimhan G, Masannat O, Chinnakotla S, et al. Liver transplantation for cystic fibrosis in adults. Surg Today. 2008;38(1):26-9.
69. Melzi ML, Kelly DA, Colombo C, Jara P, Manzanares J, Colledan M, et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int. 2006;19(9):726-31.
70. Nash KL, Collier JD, French J, McKeon D, Gimson AE, Jamieson NV, et al. Cystic fibrosis liver disease: to transplant or not to transplant? Am J Transplant. 2008;8(1):162-9.
71. Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, et al. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl. 2011;17(3):243-50.
72. Molmenti EP, Squires RH, Nagata D, Roden JS, Molmenti H, Fasola CG, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant. 2003;7(2):93-7.
73. Grannas G, Neipp M, Hoeper MM, Gottlieb J, Luck R, Becker T, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation. 2008;85(4):524-31.
74. Milkiewicz P, Skiba G, Kelly D, Weller P, Bonser R, Gur U, et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol. 2002;17(2):208-13.